GC-MS Profile of Hua-Feng-Dan and RNA-Seq Analysis of Induced Adaptive Responses in the Liver

Jiajia Liu, Yan Liang, Ya Zhang, Ruixia Wu, Yinglian Song, Feng Zhang, Jingshan Shi, Jie Liu, Shangfu Xu, Zhang WangFrontiers in Pharmacology 2022 · DOI

TL;DR

This study investigates the traditional Chinese medicine Hua-Feng-Dan (HFD) by profiling its chemical components using GC-MS and analyzing its effects on the liver transcriptome in mice via RNA-Seq. The research reveals that HFD, at doses that don't cause toxicity, activates adaptive responses in the liver, particularly related to lipid metabolism and signaling pathways, suggesting a mechanism for its therapeutic benefits.

What Problem Does This Paper Address?

Traditional Chinese Medicines (TCMs) like Hua-Feng-Dan (HFD) have a long history of use for various ailments, including stroke recovery. However, understanding the precise molecular mechanisms behind their efficacy, especially for complex multi-component formulations, remains a significant challenge. HFD is known to contain potentially toxic heavy metals like cinnabar and realgar, making it crucial to understand its safety profile and how it exerts its therapeutic effects without causing harm. This paper aims to bridge this gap by characterizing the chemical composition of HFD and elucidating its impact on the liver's molecular machinery, specifically focusing on how it might "program the liver" for protective responses.

Methods

The researchers employed a multi-pronged approach:

  • Gas Chromatography-Mass Spectrometry (GC-MS): This technique was used to identify and quantify the volatile and liposoluble chemical components within HFD. Steam distillation and solvent extraction were used to isolate these components before GC-MS analysis, with the NIST library used for compound identification.
  • Animal Studies and Drug Administration: Adult male mice were orally administered HFD and its "Guide Drug" Yaomu (YM) for seven consecutive days. Different doses of YM (0.1 g/kg and 0.3 g/kg) and a specific dose of HFD (1.2 g/kg) were used, based on previous studies.
  • Histopathology and Biochemical Analysis: Liver tissue was examined for any signs of toxicity (degeneration, necrosis) using Hematoxylin and Eosin (HE) staining. Serum enzyme activities (ALT and AST) were measured to assess liver damage.
  • RNA Sequencing (RNA-Seq): Total RNA was extracted from mouse liver tissues to analyze the global gene expression changes induced by HFD and YM treatment.
  • Bioinformatics Analysis: A suite of bioinformatics tools was used to interpret the RNA-Seq data:
  • DESeq2: To identify differentially expressed genes (DEGs) between treatment groups and controls.
  • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) Enrichment Analysis: To understand the biological processes and signaling pathways affected by the DEGs.
  • Ingenuity Pathway Analysis (IPA): To identify upstream regulators that might be driving the observed gene expression changes.
  • BaseSpace Correlation Engine (BSCE): To compare the HFD-induced gene expression patterns with existing datasets in the Gene Expression Omnibus (GEO) database to find correlations with chemical-induced adaptive responses.
  • Quantitative Real-Time PCR (qPCR): Used to validate the RNA-Seq findings for a selected set of DEGs.

Datasets

  • NIST Library: Used for the identification of chemical compounds from GC-MS analysis.
  • Gene Expression Omnibus (GEO) Database: Used in the BaseSpace Correlation Engine analysis to compare the study's DEGs with existing datasets of chemical-induced adaptive responses in mouse liver.

Key Insights and Ideas

  • "Programming the Liver": The study strongly suggests that HFD doesn't just treat symptoms but actively "programs" the liver to induce adaptive responses, making it more resilient to potential insults. This concept of "programming the liver" is a key takeaway.
  • Adaptive Responses Over Toxicity: At hepatoprotective doses, HFD did not cause liver damage. Instead, it triggered beneficial adaptive mechanisms, highlighting a crucial distinction between therapeutic and toxic effects.
  • Synergy with "Guide Drug": The "Guide Drug" Yaomu (YM) plays a role, but its effectiveness is dose-dependent. A low dose of YM showed some similar gene expression changes to HFD, while a high dose had minimal impact, underscoring the importance of precise formulation and dosage in TCM.
  • Cross-Species and Cross-Chemical Correlation: The strong correlation between HFD-induced DEGs and existing GEO datasets of chemical-induced adaptive responses suggests that HFD might be mimicking or synergizing with known adaptive pathways triggered by other compounds.

Key Results

  • Chemical Profiling: GC-MS identified 44 volatile and 50 liposoluble components in HFD. The major volatile component was endo-borneol (50.63%), and major liposoluble components included isobornyl caprate (12.33%) and endo-borneol (11.13%).
  • No Liver Toxicity: HFD and YM, at the tested doses, did not induce liver toxicity, as confirmed by histopathology and serum enzyme levels.
  • Gene Expression Changes: RNA-Seq revealed significant gene expression changes. HFD induced 806 differentially expressed genes (DEGs) compared to controls, while a low dose of YM induced 235 DEGs in a similar direction.
  • Pathway Activation: GO enrichment indicated HFD's impact on lipid homeostasis, protein folding, and cell adhesion. KEGG analysis showed activation of cholesterol metabolism, bile secretion, and PPAR signaling pathways.
  • MAPK Pathway Activation: Ingenuity Pathway Analysis (IPA) predicted the activation of MAPK signaling pathways and induced adaptive responses by HFD.
  • Validation: qPCR results largely confirmed the RNA-Seq findings for selected DEGs.

Limitations and Future Work

  • Compound Identification: While GC-MS identified numerous compounds, their exact structures were inferred from mass spectra and the NIST library. Further verification using reference standards is needed for definitive identification.
  • Complex Interactions: HFD is a complex mixture, and the study acknowledges that the identified components likely act synergistically rather than as individual pure compounds, as is common in Western medicine.
  • Further Verification: The study suggests that components like phenols, flavonoids, terpenoids, alkaloids, and glycosides, as well as trace elements, could be further analyzed by LC-MS and quantitatively assessed.
  • Dose-Response and Long-Term Effects: While the study used hepatoprotective doses, the authors caution that HFD could be hepatotoxic at high doses or with prolonged use, suggesting that caution is warranted. Future work could explore these aspects more thoroughly.
  • Mechanism of Action: While adaptive responses are identified, the precise molecular interactions and downstream effects of these pathways require further in-depth investigation.

Summary updated

Abstract

<b>Background:</b> Hua-Feng-Dan is a patent Chinese medicine for stroke recovery and various diseases. This study used GC-MS to profile its ingredients and RNA-Seq to analyze the induced adaptive response in the liver. <b>Methods:</b> Hua-Feng-Dan was subjected to steam distillation and solvent extraction, followed by GC-MS analysis. Mice were orally administered Hua-Feng-Dan and its "Guide drug" Yaomu for 7 days. Liver pathology was examined, and total RNA isolated for RNA-Seq, followed by bioinformatic analysis and quantitative real-time PCR (qPCR). <b>Results:</b> Forty-four volatile and fifty liposoluble components in Hua-Feng-Dan were profiled and analyzed by the NIST library and their concentrations quantified. The major components (>1%) in volatile (5) and liposoluble (10) were highlighted. Hua-Feng-Dan and Yaomu at hepatoprotective doses did not produce liver toxicity as evidenced by histopathology and serum enzyme activities. GO Enrichment revealed that Hua-Feng-Dan affected lipid homeostasis, protein folding, and cell adhesion. KEGG showed activated cholesterol metabolism, bile secretion, and PPAR signaling pathways. Differentially expressed genes (DEGs) were identified by DESeq2 with <i>p</i> < 0.05 compared to controls. Hua-Feng-Dan produced more DEGs than Yaomu. qPCR on selected genes largely verified RNA-Seq results. Ingenuity Pathways Analysis of the upstream regulator revealed activation of MAPK and adaptive responses by Hua-Feng-Dan, and Yaomu was less effective. Hua-Feng-Dan-induced DEGs were highly correlated with the Gene Expression Omnibus database of chemical-induced adaptive transcriptome changes in the liver. <b>Conclusion:</b> GC-MS primarily profiled volatile and liposoluble components in Hua-Feng-Dan. Hua-Feng-Dan at the hepatoprotective dose did not produce liver pathological changes but induced metabolic and signaling pathway activations. The effects of Hua-Feng-Dan on liver transcriptome changes point toward induced adaptive responses to program the liver to produce hepatoprotective effects.
BibTeX
@inproceedings{liu2022gc,
  author = {Jiajia Liu and Yan Liang and Ya Zhang and Ruixia Wu and Yinglian Song and Feng Zhang and Jingshan Shi and Jie Liu and Shangfu Xu and Zhang Wang and Shang-Fu Xu and Zhang Wang},
  title = {{GC-MS Profile of Hua-Feng-Dan and RNA-Seq Analysis of Induced Adaptive Responses in the Liver}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.730318},
}
Figure